Literature DB >> 33422407

Venous or arterial thromboses after venoarterial extracorporeal membrane oxygenation support: Frequency and risk factors.

Frank Bidar1, Aymeric Lancelot2, Guillaume Lebreton3, Marc Pineton de Chambrun1, Matthieu Schmidt4, Guillaume Hékimian1, Charles Juvin3, Nicolas Bréchot1, Thibaut Schoell3, Pascal Leprince3, Alain Combes4, Adrien Bouglé2, Charles-Edouard Luyt5.   

Abstract

BACKGROUND: Although venous thrombosis after venovenous-extracorporeal membrane oxygenation (ECMO) is well described, vascular complications occurring after venoarterial ECMO (VA-ECMO) removal have not yet been thoroughly described. Our aim was to evaluate the frequency of vascular (arterial and venous) complications after VA-ECMO removal and try to identify the risk factors associated with them.
METHODS: Retrospective analysis of data prospectively collected in 2 intensive care units was performed. Consecutive patients successfully weaned off VA-ECMO during year 1 were screened for cannula-associated deep vein thrombosis (CaDVT) or arterial complications (arterial thrombosis/stenosis) using Doppler ultrasonography.
RESULTS: From November 2018 to November 2019, a total of 107 patients with a median (interquartile range [IQR]) age of 54 (42-63) years and a median (IQR) ECMO support duration of 8 (2-5) days were successfully weaned off VA-ECMO and included. CaDVT occurred in 44 patients (41%), and arterial complications occurred in 15 (14%) (9 acute leg ischemia, 1 arteriovenous femoral fistula, and 5 late femoral stenosis). Multivariable analysis retained longer duration of ECMO support (odds ratio [OR]: 1.12 per day; 95% CI: 1.02-1.22) and infection occurring on ECMO (OR: 3.03; 95% CI: 1.14-8.03) as independent risk factors for CaDVT, whereas older age (OR: 0.97 per year; 95% CI: 0.94-0.99) and previous anti-coagulation use (OR: 0.21; 95% CI: 0.06-0.68) were protective factors for CaDVT. No risk factors for arterial complications were identified.
CONCLUSIONS: In patients requiring VA-ECMO support, vascular complications occurred frequently after its removal, especially CaDVT. Arterial complications, either early leg ischemia or late arterial stenosis, were observed less often. Strategies aimed at preventing CaDVT after VA-ECMO remain to be determined.
Copyright © 2020 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ECMO; cardiogenic shock; complication; leg ischemia; venous thrombosis

Mesh:

Year:  2020        PMID: 33422407     DOI: 10.1016/j.healun.2020.12.007

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  4 in total

1.  Bleeding and thrombotic events in adults supported with venovenous extracorporeal membrane oxygenation: an ELSO registry analysis.

Authors:  Jose I Nunez; Andre F Gosling; Brian O'Gara; Kevin F Kennedy; Peter Rycus; Darryl Abrams; Daniel Brodie; Shahzad Shaefi; A Reshad Garan; E Wilson Grandin
Journal:  Intensive Care Med       Date:  2021-12-18       Impact factor: 41.787

2.  Arterial and venous vascular complications in patients requiring peripheral venoarterial extracorporeal membrane oxygenation.

Authors:  Christoph Fisser; Corina Armbrüster; Clemens Wiest; Alois Philipp; Maik Foltan; Dirk Lunz; Karin Pfister; Roland Schneckenpointner; Christof Schmid; Lars S Maier; Thomas Müller; Matthias Lubnow
Journal:  Front Med (Lausanne)       Date:  2022-07-28

Review 3.  ECMO in neonates: The association between cerebral hemodynamics with neurological function.

Authors:  Shu-Han Yu; Dan-Hua Mao; Rong Ju; Yi-Yong Fu; Li-Bing Zhang; Guang Yue
Journal:  Front Pediatr       Date:  2022-09-06       Impact factor: 3.569

4.  Incidence and risk factors of deep vein thrombosis after extracorporeal life support.

Authors:  Olivier van Minnen; Walter M van den Bergh; Joep M Droogh; Lisette Koehorst; Wim K Lagrand; S Jorinde Raasveld; Annemieke Oude Lansink-Hartgring; Aart Terpstra; Jasper M Smit; Pieter R Tuinman; Alexander P J Vlaar
Journal:  Artif Organs       Date:  2022-04-29       Impact factor: 2.663

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.